Immunovant, Inc.IMVTNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.66% | +4.28% | +16.97% | +18.55% | +23.54% |
| Weighted Average Shares Diluted Growth | +1.66% | +4.28% | +16.97% | +18.55% | +23.54% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +116.13% | -54.37% | -19.90% | +5.01% | -26.12% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -40.83% | +16.43% | +12.17% | +13.04% | +150.01% |
| Book Value per Share Growth | -48.94% | +9.82% | -4.48% | -2.38% | +126.37% |
| Debt Growth | -92.48% | -28.99% | -100.00% | -100.00% | -100.00% |
| R&D Expense Growth | +95.54% | +41.78% | +34.09% | +17.45% | +4.66% |
| SG&A Expenses Growth | +49.69% | +36.10% | +38.37% | -5.19% | -21.96% |